返回ChemicalBook首页>CAS数据库列表>1276121-88-0

1276121-88-0

中文名称 PF-3644022
英文名称 PF 3644022
CAS 1276121-88-0
分子式 C21H18N4OS
分子量 374.46
MOL 文件 1276121-88-0.mol
更新日期 2024/06/11 23:59:59
1276121-88-0 结构式 1276121-88-0 结构式

基本信息

中文别名
化合物PF-3644022
(R)-10-甲基-3-(6-甲基吡啶-3-基)-9,10,11,12四氢-8H-[1,4]二氮杂卓并[5',6':4,5]噻吩并[3,2-F]喹啉-8-酮
英文别名
PF 3644022
MK2 INHIBITOR
(10R)-9,10,11,12-Tetrahydro-10-Methyl-3-(6-Methyl-3-pyridinyl)-8H-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinolin-8-one
8H-[1,4]Diazepino[5',6':4,5]thieno[3,2-f]quinolin-8-one, 9,10,11,12-tetrahydro-10-methyl-3-(6-methyl-3-pyridinyl)-, (10R)-

物理化学性质

熔点>180°C (dec.)
储存条件2-8°C(protect from light)
储存条件Keep in dark place,Sealed in dry,2-8°C
溶解度可溶于DMSO(少许)、甲醇(少许)
形态固体
颜色灰白色至黄色

安全数据

危险性符号(GHS)
GHS07
警示词警告
危险性描述H302-H315-H320-H335
海关编码2934999090
PF-3644022价格(试剂级)
报价日期产品编号产品名称CAS号包装价格
2024/04/30HY-107427PF-3644022
PF-3644022
1276121-88-01mg1440元
2024/04/30HY-107427PF-3644022
PF-3644022
1276121-88-05mg3400元
2024/04/30HY-107427PF-3644022
PF-3644022
1276121-88-010mM * 1mLin DMSO3960元

常见问题列表

生物活性
PF-3644022 是一种有效的,选择性的,口服活性的,具有 ATP 竞争性的 MAPKAPK2 (MK2) 抑制剂,IC50 为 5.2 nM,Ki 为 3 nM。PF-3644022 还抑制 MK3 和 p38 调节/激活激酶 (PRAK),IC50 分别为 53 nM 和 5.0 nM。PF-3644022 有效抑制 TNFα 的产生并具有抗炎作用。
靶点

IC50: 5.2 nM (MK2), 5.0 nM (PRAK) and 53 nM (MK3).
Ki: 3 nM (MK2)

体外研究

The inhibitory activity of PF-3644022 against other MAPKAP kinase family members is evaluated. Other than MNK2 with an IC 50 of 148 nM, other family members are largely not inhibited, showing at least several hundred-fold selectivity versus MK2.
In the human U937 monocytic cell line or peripheral blood mononuclear cells, PF-3644022 potently inhibits TNFα production with similar activity ( IC 50 of 160 nM). PF-3644022 blocks TNFα and IL-6 production in LPS-stimulated human whole blood with IC 50 values of 1.6 and 10.3 μM, respectively. Inhibition of TNFα in U937 cells and blood correlates closely with inhibition of phospho-heat shock protein 27, a target biomarker of MK2 activity.

体内研究

PF-3644022 (3-100 mg/kg; oral gavage; twice a day; for 12 days; Lewis rats) treatment shows dose-dependent inhibition of chronic paw swelling measured on day 21 after 12 days of oral dosing, with ED 50 value of 20 mg/kg.

Animal Model: Female Lewis rats (125-140 g) injected with streptococcal cell wall
Dosage: 3 mg/kg, 10 mg/kg, 30 mg/kg, 50 mg/kg, 100 mg/kg
Administration: Oral gavage; twice a day; for 12 days
Result: Showed dose-dependent inhibition of chronic paw swelling measured on day 21 after 12 days of oral dosing.
"1276121-88-0" 相关产品信息
1883299-62-4 1817626-54-2 1430806-04-4 1469284-78-3 1527473-33-1 1331782-27-4 1290543-63-3 869288-64-2 2230198-02-2 1334782-79-4 1197160-78-3 1469284-79-4 1013101-36-4 2468015-78-1 952021-60-2